Trial Profile
Phase II/III study of Rimeporide
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 03 May 2018
Price :
$35
*
At a glance
- Drugs Rimeporide (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 03 May 2018 New trial record
- 16 Mar 2018 According to an EspeRare Foundation media release, this trial is expected to at the end of 2018/early 2019, depending on funding.